Investing.com - Standard Biotools reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Standard Biotools announced earnings per share of $-0.370 on revenue of $25.65M. Analysts polled by Investing.com anticipated EPS of $-0.130 on revenue of $30.95M.
Standard Biotools shares are down 16% from the beginning of the year, still down 80.75% from its 52 week high of $5.09 set on November 12, 2021.
Standard Biotools follows other major Healthcare sector earnings this month
Standard Biotools's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar